Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

A E Gliddon, C J Doré, C M Black, Neil J McHugh, R Moots, C P Denton, A Herrick, T Barnes, J Camilleri, K Chakravarty, P Emery, B Griffiths, N D Hopkinson, P Hickling, P Lanyon, C Laversuch, T Lawson, R Mallya, M Nisar, C Rhys-DillonT Sheeran, P J Maddison

Research output: Contribution to journalArticlepeer-review

93 Citations (Scopus)

Abstract

Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.
Original languageEnglish
Pages (from-to)3837-46
Number of pages10
JournalArthritis & Rheumatism
Volume56
Issue number11
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril'. Together they form a unique fingerprint.

Cite this